Search

Your search keyword '"Nathan, Janak"' showing total 20 results
Start Over Author "Nathan, Janak"
20 results on '"Nathan, Janak"'

1. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma

Author

Duraj, Tomás, Kalamian, Miriam, Zuccoli, Giulio, Maroon, Joseph C., D’Agostino, Dominic P., Scheck, Adrienne C., Poff, Angela, Winter, Sebastian F., Hu, Jethro, Klement, Rainer J., Hickson, Alicia, Lee, Derek C., Cooper, Isabella, Kofler, Barbara, Schwartz, Kenneth A., Phillips, Matthew C. L., Champ, Colin E., Zupec-Kania, Beth, Tan-Shalaby, Jocelyn, Serfaty, Fabiano M., Omene, Egiroh, Arismendi-Morillo, Gabriel, Kiebish, Michael, Cheng, Richard, El-Sakka, Ahmed M., Pflueger, Axel, Mathews, Edward H., Worden, Donese, Shi, Hanping, Cincione, Raffaele Ivan, Spinosa, Jean Pierre, Slocum, Abdul Kadir, Iyikesici, Mehmet Salih, Yanagisawa, Atsuo, Pilkington, Geoffrey J., Chaffee, Anthony, Abdel-Hadi, Wafaa, Elsamman, Amr K., Klein, Pavel, Hagihara, Keisuke, Clemens, Zsófia, Yu, George W., Evangeliou, Athanasios E., Nathan, Janak K., Smith, Kris, Fortin, David, Dietrich, Jorg, Mukherjee, Purna, and Seyfried, Thomas N.

Published
2024
Full Text
View/download PDF

3. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group

Author

Kossoff, Eric H, Zupec‐Kania, Beth A, Auvin, Stéphane, Ballaban‐Gil, Karen R, Bergqvist, AG Christina, Blackford, Robyn, Buchhalter, Jeffrey R, Caraballo, Roberto H, Cross, J Helen, Dahlin, Maria G, Donner, Elizabeth J, Guzel, Orkide, Jehle, Rana S, Klepper, Joerg, Kang, Hoon‐Chul, Lambrechts, Danielle A, Liu, YM Christiana, Nathan, Janak K, Nordli, Douglas R, Pfeifer, Heidi H, Rho, Jong M, Scheffer, Ingrid E, Sharma, Suvasini, Stafstrom, Carl E, Thiele, Elizabeth A, Turner, Zahava, Vaccarezza, Maria M, Louw, Elles JTM, Veggiotti, Pierangelo, Wheless, James W, Wirrell, Elaine C, Foundation, The Charlie, Friends, Matthew's, and Society, the Practice Committee of the Child Neurology

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Complementary and Integrative Health, Nutrition, Charlie Foundation, Matthew's Friends, Practice Committee of the Child Neurology Society, Children, Diet, Epilepsy, Guideline, Ketogenic, Clinical sciences, Neurosciences, Biological psychology
Abstract

Ketogenic dietary therapies (KDTs) are established, effective nonpharmacologic treatments for intractable childhood epilepsy. For many years KDTs were implemented differently throughout the world due to lack of consistent protocols. In 2009, an expert consensus guideline for the management of children on KDT was published, focusing on topics of patient selection, pre-KDT counseling and evaluation, diet choice and attributes, implementation, supplementation, follow-up, side events, and KDT discontinuation. It has been helpful in outlining a state-of-the-art protocol, standardizing KDT for multicenter clinical trials, and identifying areas of controversy and uncertainty for future research. Now one decade later, the organizers and authors of this guideline present a revised version with additional authors, in order to include recent research, especially regarding other dietary treatments, clarifying indications for use, side effects during initiation and ongoing use, value of supplements, and methods of KDT discontinuation. In addition, authors completed a survey of their institution's practices, which was compared to responses from the original consensus survey, to show trends in management over the last 10 years.

Published
2018

5. International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies

Author

Cervenka, Mackenzie C., Wood, Susan, Bagary, Manny, Balabanov, Antoaneta, Bercovici, Eduard, Brown, Mesha-Gay, Devinsky, Orrin, Di Lorenzo, Cherubino, Doherty, Colin P., Felton, Elizabeth, Healy, Laura A., Klein, Pavel, Kverneland, Magnhild, Lambrechts, Danielle, Langer, Jennifer, Nathan, Janak, Munn, Jude, Nguyen, Patty, Phillips, Matthew, Roehl, Kelly, Tanner, Adrianna, Williams, Clare, and Zupec-Kania, Beth

Published
2021
Full Text
View/download PDF

9. Ketogenic diet treatment in diffuse intrinsic pontine glioma in children:Retrospective analysis of feasibility, safety, and survival data

Author

Perez, Alexandre, van der Louw, Elles, Nathan, Janak, El-Ayadi, Moatasem, Golay, Hadrien, Korff, Christian, Ansari, Marc, Catsman-Berrevoets, Coriene, von Bueren, Andre O., Perez, Alexandre, van der Louw, Elles, Nathan, Janak, El-Ayadi, Moatasem, Golay, Hadrien, Korff, Christian, Ansari, Marc, Catsman-Berrevoets, Coriene, and von Bueren, Andre O.

Abstract

Background: Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating diseases among children with cancer, thus novel strategies are urgently needed. Aims: We retrospectively evaluated DIPG patients exposed to the carbohydrate restricted ketogenic diet (KD) with regard of feasibility, safety, and overall survival (OS). Methods and results: Searches of MEDLINE and Embase identified five hits meeting the search criteria (diagnosis of DIPG and exposure to KD). One additional case was identified by contact with experts. Individual patient data were extracted from publications or obtained from investigators. The inclusion criteria for analysis of the data were defined as DIPG patients who were exposed to the KD for ≥3 months. Feasibility, as described in the literature, was the number of patients able to follow the KD for 3 months out of all DIPG patients identified. OS was estimated by the Kaplan-Meier method. Five DIPG patients (males, n = 3; median age 4.4 years; range, 2.5-15 years) meeting the inclusion criteria were identified. Analysis of the available data suggested that the KD is generally relatively well tolerated. Only mild gastro-intestinal complaints, one borderline hypoglycemia (2.4 mmol/L) and one hyperketosis (max 7.2 mmol/L) were observed. Five out of six DIPG patients identified adhered for ≥3 months (median KD duration, 6.5 months; range, 0.25-2 years) to the diet. The median OS was 18.7 months. Conclusion: Our study provides evidence that it may be feasible for pediatric DIPG patients to adhere for at least 3 months to KD. In particular cases, diet modifications were done. The clinical outcome and OS appear not to be impacted in a negative way. KD might be proposed as adjuvant therapy when large prospective studies have shown feasibility and safety. Future studies might ideally assess the impact of KD on clinical outcome, quality of life, and efficacy.

Published
2021

12. International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies

Author

Cervenka, Mackenzie C., primary, Wood, Susan, additional, Bagary, Manny, additional, Balabanov, Antoaneta, additional, Bercovici, Eduard, additional, Brown, Mesha-Gay, additional, Devinsky, Orrin, additional, Di Lorenzo, Cherubino, additional, Doherty, Colin P., additional, Felton, Elizabeth, additional, Healy, Laura A., additional, Klein, Pavel, additional, Kverneland, Magnhild, additional, Lambrechts, Danielle, additional, Langer, Jennifer, additional, Nathan, Janak, additional, Munn, Jude, additional, Nguyen, Patty, additional, Phillips, Matthew, additional, Roehl, Kelly, additional, Tanner, Adrianna, additional, Williams, Clare, additional, and Zupec-Kania, Beth, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results